Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer
| Autor: | Patricia A. Tang, Zachary William Neil Veitch, Derek Tilley, Domen Ribnikar, Omar Farooq Khan, Douglas A. Stewart, Xanthoula Kostaras, Sasha M. Lupichuk, Karen King |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Anthracycline Cyclophosphamide Breast Neoplasms Comorbidity Kaplan-Meier Estimate Alberta 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans 030212 general & internal medicine Aged Neoplasm Staging Retrospective Studies Taxane Cumulative dose business.industry Hazard ratio Middle Aged Prognosis medicine.disease Combined Modality Therapy Treatment Outcome Docetaxel Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female business medicine.drug Epirubicin |
| Zdroj: | Journal of the National Comprehensive Cancer Network. 17:957-967 |
| ISSN: | 1540-1413 1540-1405 |
| DOI: | 10.6004/jnccn.2019.7286 |
| Popis: | Background: Reductions in adjuvant chemotherapy dose Patients and Methods: Women with stage I–III, hormone receptor–positive/negative, HER2-negative breast cancer treated with adjuvant FEC-D chemotherapy from 2007 through 2014 in Alberta, Canada, were included. TCD for cycles 1 to 6 of Results: Characteristics were reasonably balanced for all cohorts. Overall, 1,302 patients were evaluated for dose reductions, with 16% being reduced P=.025) and OS (PP=.002 and PP=.073, and HR, 1.77; P=.011, respectively). Dose delays of Conclusions: Chemotherapy TCD |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|